Hospital Claim Denial Costs 2026: How to Stop Funding the Appeals Economy

The Hospitals Winning on Denials Are Fighting Harder Filing Differently

Most revenue cycle teams treat denials as an unavoidable cost of doing business, bringing on hundreds of dedicated appeals staff, implementing rebilling workflows, and reclaiming lost dollars through sheer persistence. That framing is becoming expensive.

The real leverage isn't in the appeals queue. It's in the conditions that produce denials in the first place, and those conditions are shifting in ways that will make reactive strategies progressively less viable.

Two concurrent policy moves from CMS are tightening the environment simultaneously: 1) prior authorization requirements are expanding into Original Medicare, and 2) transparency rules that would have made it easier to track and challenge payer denial patterns have been suspended.

The Problem, Defined in Dollars and Direction

Start with the reimbursement environment. CMS's FY 2026 IPPS proposed rule projects about $4 billion in additional inpatient Medicare reimbursement, with roughly $234 million more in payments for cases involving new medical technologies. That sounds constructive, but gross payment rate increases mean little when denial volumes erode net collections before reimbursement ever arrives.

On the home health side, the picture is more direct: CMS estimates Medicare payments to home health agencies would decrease by 6.4%, or $1.135 billion, in CY 2026 compared to CY 2025. Rate compression and denial volume are compounding problems. When base reimbursement falls and prior authorization friction increases, the margin between what a service costs to deliver and what ultimately gets paid can disappear quickly.

Across the Medicare Advantage landscape, CMS estimates the net impact of Star Ratings changes on the Medicare Trust Fund at $18.56 billion from 2027 through 2036. This estimate represents approximately 0.21% of total Medicare payments to private health plans over that period.

As Leighton Ku, a health policy expert, told FactCheck.org: "The reality is that people will receive much less health care under Medicaid because of these cuts, and health care providers like hospitals, doctors' offices and nursing homes will hurt financially because of the loss of revenue." The direction of financial pressure on providers is consistent across program lines.

What Practitioners Are Actually Experiencing

Revenue cycle directors at acute care hospitals and specialty practices have been vocal about where the friction concentrates. On professional forums and RCM communities, the consistent theme is that denials are preventable in patterns that organizations repeatedly fail to address upstream.

Prior authorization delays draw particular frustration. The authorizations that get denied on first submission often share documentation gaps, coding mismatches, or medical necessity language that doesn't align with specific payer criteria. The information needed to prevent those denials usually exists in the clinical record. The problem is whether that information gets translated into the right format before submission, not after.

The payer side of this conversation is also evolving. Nathan Frank, Chief Digital and Technology Officer at Aetna, stated directly: "We never use AI to deny prior authorizations. Any prior auth comes to a physician." Whether or not that holds consistently across all payer workflows, it signals that the clinical documentation supporting a request is under physician-level scrutiny. Submissions that read like administrative checkboxes rather than clinical arguments are at a structural disadvantage.

The Policy Shift That Changes the Calculus

Two regulatory developments in 2025 and 2026 are reordering the denial prevention landscape in ways that CFOs should understand concretely.

First, CMS announced on June 16, 2025 that it will not enforce previously finalized regulations related to utilization management and prior authorization oversight in Medicare Advantage. The suspended rules would have required MA organizations to report eight distinct metrics on PA approval and denial rates, including decision turnaround times, published at the contract level beginning in 2026. Without those metrics in the public record, RCM directors lose a benchmarking tool that would have made it easier to identify which payers deny at anomalous rates and build contract negotiation leverage accordingly.

The Georgetown Health Policy Institute's analysis of the suspension noted that beneficiaries with certain social risk factors, including those dually eligible for Medicaid, were subject to up to twice the denial rates of non-dual enrollees despite having, on average, fewer prior authorization requests. That disparity persists, but the data infrastructure that would have exposed it systematically has been shelved.

Second, CMS's Wasteful and Inappropriate Service Reduction (WISeR) model will require Original Medicare beneficiaries in six states (Washington, New Jersey, Oklahoma, Ohio, Texas, and Arizona) to obtain prior authorization for certain services beginning January 1, 2026, running through December 21, 2031. Prior authorization has historically been a Medicare Advantage dynamic. Extending it into Original Medicare represents a fundamental change in how fee-for-service claims will be processed in those markets. Providers operating in those states who have not built PA workflows for their Original Medicare volume are not prepared for what begins in January.

What Leaders Should Do Before This Gets More Expensive

Andrew Hancock, Partner and Payer/Provider Financial Solutions Leader at Guidehouse, framed the strategic priority clearly: "Our findings reinforce the need for health system leaders to invest in payer strategy and contract management to find common ground with health plans and reduce friction that slows reimbursement."

That guidance translates into concrete operational moves:

Map your denial concentration by payer and service line before year-end. If you don't know which payers are generating what share of your denial volume on which CPT codes, you're allocating appeals resources without a targeting strategy. The suspension of MA transparency reporting means you'll need to build this picture from your own claims data, payers are no longer required to hand you the benchmark.

Build PA workflows for Original Medicare in WISeR pilot states immediately. If your organization operates in Washington, New Jersey, Oklahoma, Ohio, Texas, or Arizona, the prior authorization processes your team uses for MA plans need to be adapted and tested for Original Medicare volume before January 1, 2026. The WISeR model runs for six performance years.

Audit clinical documentation against payer-specific medical necessity criteria. The gap between what a physician documents and what a payer's criteria require is where preventable denials are born. This isn't a coding audit, it's a clinical documentation alignment exercise. For surgical specialties and procedural practices where fee-for-service revenue is the primary income source, the ROI on this work is direct.

Use contract renegotiation cycles to push for denial rate transparency that CMS no longer mandates. Because CMS suspended the PA reporting requirements for MA plans, providers can pursue contractual disclosure requirements directly. Payers willing to negotiate those terms signal something meaningful about their denial practices. Payers who resist signal something equally meaningful.

Segment your appeals staff by denial type, not by payer. Authorization denials, medical necessity denials, and coding denials require different remediation paths. Teams organized by payer tend to develop muscle memory for escalation rather than prevention. Teams organized by denial type develop expertise in root cause building financial leverage.

Bottom Line

CMS is expanding prior authorization into Original Medicare while simultaneously withdrawing the transparency tools that would have helped providers identify and challenge payer denial patterns. The financial environment leaves no room for a reactive appeals operation as the primary defense. The organizations that come out of this period with stable net collection rates will be the ones that treated denial prevention as a strategic function rather than an administrative one.